These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24081217)

  • 1. Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats.
    Maeda S; Yamagishi S; Matsui T; Nakashima S; Ojima A; Maeda S; Nishino Y; Ishibashi Y; Yoshida Y; Yamakawa R
    Ophthalmic Res; 2013; 50(4):221-6. PubMed ID: 24081217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.
    Matsui T; Nishino Y; Takeuchi M; Yamagishi S
    Pharmacol Res; 2011 May; 63(5):383-8. PubMed ID: 21320599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
    Sharma AK; Kanawat DS; Mishra A; Dhakad PK; Sharma P; Srivastava V; Joshi S; Joshi M; Raikwar SK; Kurmi MK; Srinivasan BP
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):410-8. PubMed ID: 23396552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes.
    Blüher M; Schweizer A; Bader G; Foley JE
    Vasc Health Risk Manag; 2014; 10():661-4. PubMed ID: 25429228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
    Del Prato S
    Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
    Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
    J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
    Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
    Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
    Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC
    Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice.
    Wu YJ; Guo X; Li CJ; Li DQ; Zhang J; Yang Y; Kong Y; Guo H; Liu DM; Chen LM
    Metabolism; 2015 Feb; 64(2):226-35. PubMed ID: 25195070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.
    Bunck MC; Poelma M; Eekhoff EM; Schweizer A; Heine RJ; Nijpels G; Foley JE; Diamant M
    J Diabetes; 2012 Jun; 4(2):181-5. PubMed ID: 22051153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat.
    Vavrinec P; Henning RH; Landheer SW; Wang Y; Deelman LE; Dokkum RP; Buikema H
    Curr Vasc Pharmacol; 2014; 12(6):836-44. PubMed ID: 24066937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats.
    Maeda S; Matsui T; Yamagishi S
    Int J Cardiol; 2012 Jun; 158(1):171-3. PubMed ID: 22564388
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.
    Akarte AS; Srinivasan BP; Gandhi S
    Eur J Pharm Sci; 2012 Apr; 45(5):546-51. PubMed ID: 22155545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vildagliptin in clinical practice: a review of literature.
    Banerjee M; Younis N; Soran H
    Expert Opin Pharmacother; 2009 Nov; 10(16):2745-57. PubMed ID: 19874253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure and fasting lipid changes after 24 weeks' treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus.
    Evans M; Schweizer A; Foley JE
    Vasc Health Risk Manag; 2016; 12():337-40. PubMed ID: 27574437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
    Panina G
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():32-9. PubMed ID: 17877545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vildagliptin].
    Iwamoto Y
    Nihon Rinsho; 2011 May; 69(5):865-70. PubMed ID: 21595273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.